{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:36:08Z","timestamp":1761964568429},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1479-5876-12-131","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T05:04:36Z","timestamp":1400216676000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?"],"prefix":"10.1186","volume":"12","author":[{"given":"Audrey","family":"Mansuet-Lupo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouzia","family":"Zouiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Alifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Ducruit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Devez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Blons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"1846_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med. 2008, 359: 1367-1380. 10.1056\/NEJMra0802714.","journal-title":"N Engl J Med"},{"key":"1846_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/modpathol.2010.232","volume":"24","author":"A Yoshizawa","year":"2011","unstructured":"Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD: Impact of proposed IASLC\/ATS\/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011, 24: 653-664. 10.1038\/modpathol.2010.232.","journal-title":"Mod Pathol"},{"key":"1846_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1470-2045(09)70155-X","volume":"10","author":"LE Coate","year":"2009","unstructured":"Coate LE, John T, Tsao MS, Shepherd FA: Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009, 10: 1001-1010. 10.1016\/S1470-2045(09)70155-X.","journal-title":"Lancet Oncol"},{"key":"1846_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.1101637","volume":"305","author":"R Sordella","year":"2004","unstructured":"Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004, 305: 1163-1167. 10.1126\/science.1101637.","journal-title":"Science"},{"key":"1846_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056\/NEJMoa040938.","journal-title":"N Engl J Med"},{"key":"1846_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.2006.06.8015","volume":"25","author":"J Subramanian","year":"2007","unstructured":"Subramanian J, Govindan R: Lung cancer in never smokers: a review. J Clin Oncol. 2007, 25: 561-570. 10.1200\/JCO.2006.06.8015.","journal-title":"J Clin Oncol"},{"key":"1846_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1349-7006.2007.00607.x","volume":"98","author":"T Mitsudomi","year":"2007","unstructured":"Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007, 98: 1817-1824. 10.1111\/j.1349-7006.2007.00607.x.","journal-title":"Cancer Sci"},{"key":"1846_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1440-1827.2007.02098.x","volume":"57","author":"Y Yatabe","year":"2007","unstructured":"Yatabe Y, Mitsudomi T: Epidermal growth factor receptor mutations in lung cancers. Pathol Int. 2007, 57: 233-244. 10.1111\/j.1440-1827.2007.02098.x.","journal-title":"Pathol Int"},{"key":"1846_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M: EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013, 12: 220-229. 10.1158\/1535-7163.MCT-12-0620.","journal-title":"Mol Cancer Ther"},{"key":"1846_CR10","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Janne PA: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006, 12: 3908-3914. 10.1158\/1078-0432.CCR-06-0462.","journal-title":"Clin Cancer Res"},{"key":"1846_CR11","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","volume":"17","author":"JY Wu","year":"2011","unstructured":"Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC: Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011, 17: 3812-3821. 10.1158\/1078-0432.CCR-10-3408.","journal-title":"Clin Cancer Res"},{"key":"1846_CR12","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011, 29: 2866-2874. 10.1200\/JCO.2010.33.4235.","journal-title":"J Clin Oncol"},{"key":"1846_CR13","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/ijc.23868","volume":"123","author":"SX Jiang","year":"2008","unstructured":"Jiang SX, Yamashita K, Yamamoto M, Piao CJ, Umezawa A, Saegusa M, Yoshida T, Katagiri M, Masuda N, Hayakawa K, Okayasu I: EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer. 2008, 123: 2480-2486. 10.1002\/ijc.23868.","journal-title":"Int J Cancer"},{"key":"1846_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/JTO.0b013e318168be93","volume":"3","author":"A Sakurada","year":"2008","unstructured":"Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS: Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008, 3: 527-529. 10.1097\/JTO.0b013e318168be93.","journal-title":"J Thorac Oncol"},{"key":"1846_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1349-7006.2008.00782.x","volume":"99","author":"K Taniguchi","year":"2008","unstructured":"Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008, 99: 929-935. 10.1111\/j.1349-7006.2008.00782.x.","journal-title":"Cancer Sci"},{"key":"1846_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00280-011-1791-9","volume":"69","author":"JN Jakobsen","year":"2012","unstructured":"Jakobsen JN, Sorensen JB: Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol. 2012, 69: 289-299. 10.1007\/s00280-011-1791-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1846_CR17","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1200\/JCO.2010.33.3906","volume":"29","author":"Y Yatabe","year":"2011","unstructured":"Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011, 29: 2972-2977. 10.1200\/JCO.2010.33.3906.","journal-title":"J Clin Oncol"},{"key":"1846_CR18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2559.2012.04245.x","volume":"61","author":"JS Mattsson","year":"2011","unstructured":"Mattsson JS, Imgenberg-Kreuz J, Edlund K, Botling J, Micke P: Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology. 2011, 61: 744-751.","journal-title":"Histopathology"},{"key":"1846_CR19","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011, 17: 1616-1622. 10.1158\/1078-0432.CCR-10-2692.","journal-title":"Clin Cancer Res"},{"key":"1846_CR20","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","volume":"17","author":"R Rosell","year":"2011","unstructured":"Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, De Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011, 17: 1160-1168. 10.1158\/1078-0432.CCR-10-2158.","journal-title":"Clin Cancer Res"},{"key":"1846_CR21","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1200\/JCO.2006.06.5961","volume":"24","author":"E Calvo","year":"2006","unstructured":"Calvo E, Baselga J: Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006, 24: 2158-2163. 10.1200\/JCO.2006.06.5961.","journal-title":"J Clin Oncol"},{"key":"1846_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12: 175-180. 10.1016\/S1470-2045(10)70087-5.","journal-title":"Lancet Oncol"},{"key":"1846_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D: International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011, 6: 244-285. 10.1097\/JTO.0b013e318206a221.","journal-title":"J Thorac Oncol"},{"key":"1846_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.yexmp.2012.03.001","volume":"92","author":"A Didelot","year":"2012","unstructured":"Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H: Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol. 2012, 92: 275-280. 10.1016\/j.yexmp.2012.03.001.","journal-title":"Exp Mol Pathol"},{"key":"1846_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/mc.20538","volume":"48","author":"K Pallier","year":"2009","unstructured":"Pallier K, Houllier AM, Le Corre D, Cazes A, Laurent-Puig P, Blons H: No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer. Mol Carcinog. 2009, 48: 581-585. 10.1002\/mc.20538.","journal-title":"Mol Carcinog"},{"key":"1846_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006\/meth.2001.1262.","journal-title":"Methods"},{"key":"1846_CR27","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","volume":"26","author":"LV Sequist","year":"2008","unstructured":"Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008, 26: 2442-2449. 10.1200\/JCO.2007.14.8494.","journal-title":"J Clin Oncol"},{"key":"1846_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/fon.13.6","volume":"9","author":"M Santarpia","year":"2013","unstructured":"Santarpia M, De Pas TM, Altavilla G, Spaggiari L, Rosell R: Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol. 2013, 9: 327-345. 10.2217\/fon.13.6.","journal-title":"Future Oncol"},{"key":"1846_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11523-013-0258-9","volume":"8","author":"K Kobayashi","year":"2013","unstructured":"Kobayashi K, Hagiwara K: Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol. 2013, 8: 27-33. 10.1007\/s11523-013-0258-9.","journal-title":"Target Oncol"},{"key":"1846_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1634\/theoncologist.2011-0385","volume":"17","author":"ZY Chen","year":"2012","unstructured":"Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL: EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012, 17: 978-985. 10.1634\/theoncologist.2011-0385.","journal-title":"Oncologist"},{"key":"1846_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2012.07.003","volume":"78","author":"Y Honda","year":"2012","unstructured":"Honda Y, Takigawa N, Fushimi S, Ochi N, Kubo T, Ozaki S, Tanimoto M, Kiura K: Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors. Lung Cancer. 2012, 78: 121-124. 10.1016\/j.lungcan.2012.07.003.","journal-title":"Lung Cancer"},{"key":"1846_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11523-012-0241-x","volume":"8","author":"K Shimizu","year":"2012","unstructured":"Shimizu K, Yukawa T, Hirami Y, Okita R, Saisho S, Maeda A, Yasuda K, Nakata M: Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol. 2012, 8: 237-242.","journal-title":"Target Oncol"},{"key":"1846_CR33","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","volume":"15","author":"K Schmid","year":"2009","unstructured":"Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M: EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009, 15: 4554-4560. 10.1158\/1078-0432.CCR-09-0089.","journal-title":"Clin Cancer Res"},{"key":"1846_CR34","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdn679","volume":"20","author":"CH Gow","year":"2009","unstructured":"Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009, 20: 696-702. 10.1093\/annonc\/mdn679.","journal-title":"Ann Oncol"},{"key":"1846_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/sj.bjc.6604629","volume":"99","author":"A Kalikaki","year":"2008","unstructured":"Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008, 99: 923-929. 10.1038\/sj.bjc.6604629.","journal-title":"Br J Cancer"},{"key":"1846_CR36","doi-asserted-by":"publisher","first-page":"e54170","DOI":"10.1371\/journal.pone.0054170","volume":"8","author":"H Bai","year":"2013","unstructured":"Bai H, Wang Z, Wang Y, Zhuo M, Zhou Q, Duan J, Yang L, Wu M, An T, Zhao J, Wang J: Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One. 2013, 8: e54170-10.1371\/journal.pone.0054170.","journal-title":"PLoS One"},{"key":"1846_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-9966-30-30","volume":"30","author":"L Sun","year":"2011","unstructured":"Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B: Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res. 2011, 30: 30-10.1186\/1756-9966-30-30.","journal-title":"J Exp Clin Cancer Res"},{"key":"1846_CR38","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1093\/annonc\/mds121","volume":"23","author":"K Goto","year":"2012","unstructured":"Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, Whiteley J, Donald E, McCormack R, Todo T: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012, 23: 2914-2919. 10.1093\/annonc\/mds121.","journal-title":"Ann Oncol"},{"key":"1846_CR39","first-page":"10","volume":"3","author":"C Ma","year":"2011","unstructured":"Ma C, Wei S, Song Y: T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011, 3: 10-18.","journal-title":"J Thorac Dis"},{"key":"1846_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","volume":"66","author":"G Ellison","year":"2012","unstructured":"Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R: EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2012, 66: 79-89.","journal-title":"J Clin Pathol"},{"key":"1846_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-9966-33-5","volume":"33","author":"B Wei","year":"2014","unstructured":"Wei B, Yang K, Zhao J, Chang Y, Ma Z, Dong B, Guo Y, Ma J: Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer. J Exp Clin Cancer Res. 2014, 33: 5-10.1186\/1756-9966-33-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"1846_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1245\/s10434-010-1295-6","volume":"18","author":"YL Chang","year":"2011","unstructured":"Chang YL, Wu CT, Shih JY, Lee YC: Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol. 2011, 18: 543-50. 10.1245\/s10434-010-1295-6.","journal-title":"Ann Surg Oncol"},{"key":"1846_CR43","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/ijc.21940","volume":"119","author":"S Matsumoto","year":"2006","unstructured":"Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006, 119: 1491-4. 10.1002\/ijc.21940.","journal-title":"Int J Cancer"},{"key":"1846_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1525-1578(10)60006-2","volume":"7","author":"M Akbari","year":"2005","unstructured":"Akbari M, Hansen MD, Halgunset J, Skorpen F, Krokan HE: Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn. 2005, 7: 36-39. 10.1016\/S1525-1578(10)60006-2.","journal-title":"J Mol Diagn"},{"key":"1846_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.lungcan.2012.11.009","volume":"79","author":"TJ Grob","year":"2012","unstructured":"Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK, Klose H, Simon R, Pantel K, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W: Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer. 2012, 79: 221-227.","journal-title":"Lung Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-12-131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:54:05Z","timestamp":1630554845000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-12-131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-12-131","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]},"assertion":[{"value":"5 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"131"}}